$Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial$

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial

.

Saved in:

Bibliographic Details
Main Authors:	M. S. Brose, F. P. Worden, K. L. Newbold, M. Guo, A. Hurria
Format:	Article
Language:	Russian
Published:	ABV-press 2018-07-01
Series:	Опухоли головы и шеи
Subjects:	lenvatinib radioiodine-refractory differentiated cancer thyroid
Online Access:	https://ogsh.abvpress.ru/jour/article/view/346
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)
by: Giulia Puliani, et al.
Published: (2025-04-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis
by: Congcong Wang, et al.
Published: (2025-08-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
by: E. V. Borodavina, et al.
Published: (2020-11-01)

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
by: Majid Assadi, et al.
Published: (2019-10-01)

Effectiveness of radioiodine therapy on preventing recurrence in differentiated thyroid carcinoma: a systematic review
by: Bima Indra, et al.
Published: (2025-05-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy
by: Leo Hashimoto, et al.
Published: (2025-07-01)

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

Low-Dose Versus Standard-Dose Radioiodine Therapy in Differentiated Thyroid Cancer: Focus on Tolerability in a Retrospective Evaluation
by: Laura Musso, et al.
Published: (2025-03-01)

TSHR in thyroid cancer: bridging biological insights to targeted strategies
by: Shaojie Xu, et al.
Published: (2025-07-01)

Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
by: Jan Taprogge, et al.
Published: (2025-07-01)

Survival analysis of patients with advanced metastatic differentiated thyroid cancer
by: E. V. Borodavina, et al.
Published: (2022-08-01)

Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre
by: Monica Majumder, et al.
Published: (2025-06-01)

Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib
by: E. B. Vasilyeva, et al.
Published: (2024-06-01)

Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
by: Nguyen Thi Phuong, et al.
Published: (2024-12-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece
by: George Simeakis, et al.
Published: (2025-01-01)

Progress and prospect on treatment for radioiodine-refractory thyroid cancer
by: GENG Qianqian, YANG Aimin
Published: (2025-01-01)

“Tumour sink effect” on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: An uncommon but possible phenomenon in thyroid cancer practice
by: Sandip Basu, et al.
Published: (2020-04-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

Comparison of radioiodine ablation rates between low versus high dose, and according to the surgeon's expertise in the low-risk group of differentiated thyroid cancer
by: Ghazal Norouzi, et al.
Published: (2021-03-01)

The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
by: WANG Renfei, LU Gaixia
Published: (2025-01-01)

Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study
by: John S. Vekinis, et al.
Published: (2025-08-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report
by: Haruhiko Yamazaki, et al.
Published: (2023-03-01)

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
by: E. B. Vasil’eva, et al.
Published: (2018-04-01)

Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription
by: Mehran Pashnehsaz, et al.
Published: (2016-07-01)

Management of radioiodine ablation therapy in haemodialysis patients with thyroid cancer: a case series of two patients
by: Raymond Lin, et al.
Published: (2025-07-01)